Royalty Pharma plc announced on June 24, 2025, a substantial funding arrangement of up to $2 billion with Revolution Medicines. This agreement is designed to support the global development and commercialization of daraxonrasib, an experimental cancer drug, and Revolution Medicines' broader pipeline for RAS-addicted cancers.
The funding package comprises a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million. This customized funding solution allows Revolution Medicines to retain operational control over its clinical development and commercialization efforts.
Daraxonrasib, a RAS(ON) multi-selective inhibitor, is currently in Phase 3 development for RAS mutant pancreatic cancer and non-small cell lung cancer (NSCLC). These cancers represent significant unmet needs, with approximately 56,000 U.S. patients diagnosed with RAS-driven pancreatic cancer and 60,000 with RAS-driven NSCLC annually. Phase 3 results for daraxonrasib in pancreatic cancer are expected in 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.